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Abstract
Background—The kappa opioid receptor (KOR) and its endogenous agonist, the neuropeptide
dynorphin, are a critical component of the central stress system. Both dynorphin and KOR are
expressed in the bed nucleus of the stria terminalis (BNST), a brain region associated with anxiety
and stress. This suggests that KOR activation in this region may play a role in the regulation of
emotional behaviors. To date, however, there has been no investigation of the ability of KOR to
modulate synaptic transmission in the BNST.
Methods—We used whole-cell patch clamp recordings from acutely prepared mouse brain slices
to examine the actions of KOR on inhibitory transmission in the BNST. Additionally, we used
neurochemical and pathway-specific optogenetic manipulations to selectively stimulate
GABAergic fibers from the central nucleus of the amygdala (CeA) to the BNST.
Results—We found that activation of KOR reduced GABAergic transmission through a
presynaptic mechanism. Futhermore, we examined the signal transduction pathways that mediate
this inhibition, and provide the first functional information implicating ERK in KOR-mediated
presynaptic modulation. Moreover, we found that at KOR-signaling robustly reduced inhibitory
synaptic transmission in the CeA to BNST pathway.
Conclusions—Together, these results demonstrate that KOR provide important inhibitory
control over presynaptic GABAergic signaling within the BNST, and provide the first direct
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functional demonstration of KOR sensitive long-range GABAergic connections between the CeA
and the BNST.
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Introduction
Affective disorders, including depression, anxiety, and addiction, are widespread and take a
tremendous toll on society. Recent work suggests that neuropeptide signaling systems are
involved in the modulation of behaviors associated with these affective disorders and thus
are potential targets for their treatment (1). In particular, the neuropeptide dynorphin, an
endogenous agonist for the kappa opioid receptor (KOR), has been suggested to play a
critical role in affective disorders and reward (2–5). Recent studies have shown that KOR
signaling is involved in stress-induced behaviors including dysphoria (6), relapse to cocaine
seeking (7), and analgesia (8), as well as in anxiety (5, 9) and depression (4). In addition,
KOR signaling has been shown to modulate synaptic transmission of classic
neurotransmitter systems in a variety of brain regions involved in reward, including the
ventral tegmental area and the nucleus accumbens (10–13). However, KOR modulation of
synaptic transmission in the extended amygdala, which is important for the regulation of
both stress- and reward-related behaviors, has not yet been examined.
The extended amygdala is a series of extensively interconnected structures including the bed
nucleus of the stria terminalis (BNST) and the central nucleus of the amygdala (CeA). A
large body of evidence from the Davis group has demonstrated that the CRF originating in
the CeA acts within the BNST, via CRF1 receptors to gate the switch from a phasic to tonic
fear (14, 15). It was hypothesized that this was due to a CRF dependent increase in
glutamate transmission, which was demonstrated by Kash et al in 2008 (16). However,
recent reports from the Chavkin group have suggested that the actions of CRF are due in
part to activation of KOR systems. Despite the important role that CRF signaling plays in
this region, there is no data suggesting what KOR activation does in the BNST. Both
dynorphin and KORs are expressed in neurons of both the BNST and CeA (17), and
evidence suggests that there is a population of GABAergic neurons in the CeA that express
dynorphin and project to the BNST (18). Further, a recent imaging study found that
administration of a KOR agonist led to metabolic activation in the BNST (19). Thus, KOR
activation in the BNST, potentially caused by dynorphin release from CeA neurons that
terminate in the BNST, may have a significant effect on the function of BNST neurons that
project to downstream targets involved in anxiety and reward-related behaviors, including
the paraventricular nucleus of the hypothalamus, dorsal raphe, and ventral tegmental area. In
this study, we examined the mechanism by which KOR activation alters synaptic
transmission in the BNST. Further, using optogenetics in a knock-in mouse that allows
targeting of genetically-defined GABAergic neurons, we directly probed the ability of KOR
activation to alter GABAergic synaptic transmission from the CeA to the BNST.
Methods
Animals
Male C57BL/6J mice were acquired from Jackson Laboratories (Bar Harbor, ME) at 5
weeks of age and housed in our colony room under a 12:12 hr light cycle, with lights on at 7
a.m. daily. Mice were given ad libitum access to rodent chow and water. All procedures
were performed in accordance with the Institutional Animal Care and Use Committee at the
University of North Carolina at Chapel Hill.
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Brain slices containing dorsolateral BNST were obtained (see Supplemental Information for
details) and stored in a heated, oxygenated holding chamber containing ACSF [(in mM) 124
NaCl, 4.4 KCl, 2 CaCl2, 1.2 MgSO4, 1 NaH2PO4, 10.0 glucose, and 26.0 NaHCO3] before
being transferred to a submerged recording chamber maintained at approximately 30 °C
(Warner Instruments, Hamden, CT). Recording electrodes were filled with (in mM) 70 KCl ,
65 K+-gluconate, 5 NaCl, 10 HEPES, 2 QX-314, 0.6 EGTA, 4 ATP, 0.4 GTP, pH 7.2, 290–
295 mOsmol. Pilot data demonstrate similar effects of KOR agonists using a cesium-based
internal solution (see Supplemental Information).
Cells were held at −70 mV and spontaneous (sIPSCs) and evoked IPSCs (eIPSCs) were
pharmacologically isolated by adding either 3 mM kynurenic acid to block AMPA and
NMDA receptor-dependent postsynaptic currents or NBQX (10 μM) to block AMPA
receptor-dependent post-synaptic currents. In pilot experiments, we found no differences in
the effects of U69593 or dynorphin in the presence of these different glutamate receptor
antagonists. To isolate miniature IPSCs (mIPSCs), tetrodotoxin (0.5 μM) was added to the
perfusing ACSF solution described above.
Electrode stimulation-evoked GABAergic IPSCs were induced via twisted bipolar nichrome
wire placed dorsal to the recording electrode, 100–500 μm medial from the recorded neuron.
Electric output was set to stimulate at 0.1 Hz, between 5–50 V with a 100–150 μs duration.
For light-evoked IPSCs, a blue LED light (Thorlabs) routed through the epifluoresnce port
and the objective was used to optically stimulate ChR2-positive fibers. Light output was set
to 2 mW with 1–5 ms pulse durations. Signals were acquired via a Multiclamp 700B
amplifier (Molecular Devices), digitized at 10 kHz, filtered at 3 kHz, and analyzed using
Clampfit 10.2 software (Molecular Devices). Input resistance and access resistance were
continuously monitored during experiments. Experiments in which changes in access
resistance were greater than 20% were not included in the data analysis. Evoked IPSC
experiments were analyzed by measuring the average peak amplitude of the synaptic
response per minute, which was normalized to the baseline period 5 min immediately
preceding application of the drug. No more than two cells per animal were included in each
experiment. All drug information can be located in the Supplemental Information.
Stereotaxic surgery
Mice (heterozygous vGAT-ires-Cre for targeting GABAergic neurons (20)) received
bilateral CeA injections of 0.3 – 0.5 μl of purified and concentrated AAV (~1012 infectious
units/mL). Further details regarding stereotaxic surgery are included in Supplemental
Information.
Statistical analysis
Effects of drugs during electrophysiological recordings were evaluated by comparing the
magnitude of the dependent measure (peak eIPSC amplitude, sIPSC/mIPSC frequency, or
sIPSC/mIPSC amplitude) between the baseline and washout (when drug had reached
maximal effect) periods using t-tests. The effects of antagonists/blockers on the ability of
drugs to modulate synaptic transmission were compared using t-tests during the washout
period. All values given for drug effects throughout the paper are presented as mean ±
S.E.M.
Results
We examined the effects of KOR activation on inhibitory synaptic transmission in the
dorsolateral BNST, focusing our efforts on the oval subnucleus and utilizing whole-cell
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voltage clamp of neurons from acutely prepared brain slices of adult C57BL/6J mice. Local
stimulation in the BNST produced an eIPSC that was driven by activation of GABAARs, as
the selective GABAAR antagonists, SR95531 and picrotoxin (data not shown), blocked the
response. Additionally, we observed spontaneous IPSCs (sIPSCs) (frequency: 1.92 ± 0.6 Hz,
n = 6 cells; amplitude: 74 ± 10 pA, n = 6 cells) that were blocked by SR95531, suggesting
that these events were also mediated by GABAA receptors (data not shown).
Dynorphin depresses GABAergic transmission through activation of KOR
To assess the impact of KOR activation on GABAergic transmission, we first investigated
the effect of dynorphin on eIPSCs. Ten min bath application of dynorphin A (300 nM)
significantly decreased the peak amplitude of the eIPSC to 64 ± 8 % of baseline (p < 0.05,
Figure 1A–C), which was observed in 5/5 cells. To verify that KOR is the receptor
underlying the actions of dynorphin, we demonstrated that pre-application of the selective
KOR antagonist norbinaltorphimine (nor-BNI, 100 nM) blocked dynorphin-induced
decreases in eIPSCs in the BNST (94 ± 5 % of baseline, n =5, Figure 1B). We next
examined the impact of a KOR selective agonist, U69593, on GABAergic transmission. We
found that bath application of U69593 (1 μM) significantly decreased the peak amplitude of
the eIPSC to 77 ± 8% of the baseline (p < 0.05, n =6, Figure 1D). Similar to what was
observed with dynorphin, this effect was blocked by pre-application of 100 nM nor-BNI
(Figure 1D, 102 ± 5% of the baseline, n = 5). Importantly, this effect does not appear to be a
long-term depression, as application of the KOR antagonist (100 nM nor-BNI) following
removal of agonist reverses the inhibition (Figure 1C). To assess tonic KOR activation by
endogenous dynorphin, 100nM nor-BNI was bath-applied alone, and we found no effects on
baseline transmission (104 ± 2% of the baseline, Figure 1E). Taken together, these results
(summarized in Figure 1F) demonstrate that activation of KOR in the BNST leads to a
reduction of GABAergic transmission.
Mechanism of KOR inhibition of GABAergic transmission
To determine whether KOR-mediated suppression of GABAergic activity occurred pre- or
postsynaptically we utilized multiple well-established approaches. We first examined the
impact of reducing the concentrations of extracellular calcium. Previous studies have shown
that altering the external calcium concentration can increase the extent of the inhibition
when it is mediated presynaptically (21). To understand the site of action for KOR-mediated
inhibition of GABAergic transmission in the BNST, we examined the actions of U69593 in
an external calcium concentration of 1.0 mM. We found that in reduced external calcium,
the effect of 1 μM U69593 was significantly increased compared to the experiments
performed in normal ACSF that contains 2.0 mM calcium (Figure 2A, B). This finding
suggests that KOR-mediated inhibition of GABAergic transmission in the BNST occurs
presynaptically. We next examined the impact of U69593 on spontaneous inhibitory
synaptic transmission. The basal frequency and amplitude for sIPSC were 1.92 ± 0.6 Hz and
74 ± 10 pA, respectively (n = 6). In most situations, presynaptic modulation alters the
frequency of events, while post-synaptic modulation alters the amplitude of events. We
found that bath application of 1 μM U69593 led to a significant reduction in the frequency
of sIPSCs (68 ± 12% of baseline, p < 0.05, n =6, Figure 3D, E) without an effect on sIPSC
amplitude (106 ± 14% of baseline, n =6, Figure 3C, E), further supporting the possibility
that KORs modulate presynaptic function at GABAergic synapses.
One potential explanation for our results is that KORs inhibit the firing of a population of
local GABAergic interneurons post-synaptically, leading to reduced GABA release within
the BNST. We evaluated this possibility by examining the impact of U69593 on miniature
inhibitory post-synaptic currents (mIPSCs). mIPSCs are similar to sIPSCs, however, the
sodium channel blocker, tetrodotoxin, is added to prevent action-potential coupled GABA
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release. The basal frequency and amplitude for mIPSC were 1.24 ± 0.6 Hz and 37 ± 9 pA,
respectively (n = 6). mIPSC amplitude, but not frequency, was significantly lower than that
of sIPSC (p < 0.05). We found that bath application of 1 μM U69593 significantly reduced
mIPSC frequency (67 ± 2% of baseline, p < 0.05, n =5) with no effect on mIPSC amplitude
(102 ± 8% of baseline, n =5), suggesting that these effects are mediated at the synapse rather
than via altering excitability of local interneurons (Figure 3F).
To more rigorously evaluate the mechanisms underlying this modulation, we next examined
two parameters that are related to presynaptic release properties: paired pulse ratio (PPR)
and coefficient of variation (CV) (22). PPR is examined by looking at the ratio of the
amplitudes of two synaptic events evoked within a short time period (for example, 50 ms).
CV is defined as σ/μ, where σ is the standard deviation of IPSC amplitude and μ is the mean
IPSC amplitude. At most central synapses, changes in PPR are associated with
modifications of the release probability, while changes in CV are associated with alterations
in the release probability and the number of release sites. We tested the utility of these
approaches in the BNST by performing a series of positive and negative control experiments
for presynaptic modulation.
GABAB receptors act as autoreceptors in many regions of the brain at GABAergic synapses,
providing negative feedback on to inhibitory terminals (23). We therefore examined the
impact of GABAB receptor activation on eIPSCs recorded from BNST neurons. We found
that bath application of 100 nM baclofen, a GABAB receptor agonist, lead to a similar
reduction of eIPSC amplitude (58 ± 8% of baseline, p < 0.05, n =6, Figure 4A, C) as a KOR
agonist. Further, this reduction was associated with a significant increase in both the PPR
(198 ± 35 % of baseline, p < 0.05, n = 6, Figure 4B, I) and the CV (172 ± 21 % of baseline,
p < 0.05, n = 6, Figure 4J), consistent with the ability of GABAB receptors to regulate
GABA release. We next examined the impact of reducing the stimulation intensity, a
manipulation that should reduce the number of release sites but have no effect on the
probability of release (22). As expected, we found that reducing stimulation intensity lead to
a significant reduction in eIPSC amplitude (49 ± 4% of baseline, p < 0.05, n =5, Figure 4E)
with no change in PPR (103 ± 7 % of baseline, n = 5, Figure 4F, I), but a significant increase
in CV (167 ± 14 % of baseline, p < 0.05, n = 5, Figure 4J). Finally, we examined the impact
of a manipulation with no predicted effect on either CV or PPR – application of a sub-
saturating concentration of the GABAA-R antagonist picrotoxin. Application of 5 μM
picrotoxin significantly reduced eIPSC amplitude (46 ± 3% of baseline, p < 0.05, n =5,
Figure 4G) but had no effect on either CV (96 ± 9 % of baseline, n = 5, Figure 4J) or PPR
(104 ± 8 % of baseline, n = 5, Figure 4H, I). Taken together, the results from these
experiments strongly support the use of CV and PPR as tools to evaluate presynaptic
function in the BNST.
Having confirmed the utility of these approaches to measure changes in presynaptic function
in our slice preparation, we next examined the effect of both dynorphin and U69593 on PPR.
Surprisingly, we found that neither 300 nM dynorphin (97 ± 5 % of baseline, n = 5, Figure
5A), nor 1 μM U69593 (97 ± 4 % of baseline, n = 6, Figure 5B), had any measurable effect
on the PPR of eIPSCs in the BNST (Figure 5C). In contrast, both compounds lead to small
but significant increases in CV (dynorphin: 122 ± 8% of baseline, p < 0.05, n =5; U69593:
113 ± 8% of baseline, p < 0.05, n =5; Figure 5D). Collectively, these findings support the
possibility that KOR activation in the BNST is altering presynaptic GABA function,
possibly through a reduction in presynaptic release sites.
The role of MAPK signaling in KOR modulation of GABAergic transmission
Next, we investigated the underlying signaling cascades that are involved in KOR-mediated
inhibition of GABA release in the BNST. Reports have demonstrated that KOR can activate
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MAPK signaling pathways including p38MAPK and ERK1/2 and that these pathways could
be activated by exposure to stress (24–26). To determine if KOR signaling through these
pathways was responsible for the reduction of GABA release in the BNST, we investigated
the impact of a series of well-characterized pharmacological probes. To determine if
p38MAPK signaling was required for KOR-mediated inhibition of GABA release, we bath
applied the p38MAPK inhibitor (27), SB203580 (20 μM), for at least 45 minutes prior to
beginning the experiment. This compound had no effect on the ability of 1 μM U69593 to
inhibit eIPSCs in the BNST (66 ± 9 % of baseline, n = 6, Figure 6A, B). To determine if
ERK signaling was required for KOR-mediated inhibition of GABA release, we applied
U69593 (1 μM) to BNST slices in the presence of the mitogen-activated protein kinase
(MAPK) kinase (MEK) inhibitors U0126 (20 μM) or SL327 (10 μM) while recording
eIPSCs. The presence of U0126 or SL327 blocked the ability of U69593 to reduce eIPSC
peak amplitude when compared to drug alone (U0126: p < 0.05, 94 ± 4 % of baseline, n = 6.
SL327: p < 0.05, 104 ± 13 % of baseline, n = 6, Figure 6A, B). Interestingly, bath
application of both MEK inhibitors, U0126 and SL327, alone slightly but significantly
increased eIPSC amplitude (U0126: p < 0.05, 133 ± 9 % of baseline, n = 5. SL327; p < 0.05,
115 ± 6 % of baseline, n = 6 . Figure 6C, D), suggesting a critical role of ERK1/2 signaling
in the regulation of GABAergic transmission. In order to determine if the effect of the MEK
inhibitors generalized to other forms of presynaptic inhibition, we next evaluated the ability
of U0126 to modulate baclofen induced inhibition of GABAergic transmission. In contrast
to the effects on U69593, we found that U0126 had no effect on baclofen-induced inhibition
(Figure 6E, F). Taken together, these results (summarized in Figure 6B, F) provide the first
evidence that the ability of KOR to inhibit GABA release is dependent on ERK signaling.
Optogenetic control of the CeA-to-BNST pathway
We sought to directly evaluate the sensitivity of the GABAergic projection from the CeA to
the BNST using a newly generated knock-in Cre line (vGAT-ires-Cre). This pathway has
been hypothesized to play a critical role in anxiety, stress-induced relapse, and alcohol
abuse. In order to isolate the CeA-BNST pathway, we injected a double-floxed virus
containing channelrhodopsin (ChR2) tagged to YFP (in mice used for electrophysiology
data) or GFP (in the mouse used for imaging in Figure 7) into the CeA of vGat-ires-Cre
mice. A pilot study using whole-cell patch-clamp recordings confirmed that blue LED light
could depolarize ChR2-positive, YFP-expressing GABA neurons in the CeA (Figure 7C).
Successful viral transduction of neurons in the CeA (Figure 7A) also resulted in robust
expression of YFP-positive fibers in the BNST (Figure 7B). As shown in Figure 7C, a 5 ms
light stimulation led to a picrotoxin-sensitive IPSC in the BNST, demonstrating that we
were able to use ChR2 to specifically activate CeA to BNST GABAergic projection
neurons. Using epifluorescence to visualize YFP in cell bodies in the CeA and terminals in
the BNST, we confirmed that virus injections to the CeA were successful in seven of 10
hemispheres. We were able to evoke time-locked IPSCs with blue LED light in neurons
from all BNST slices in these seven successfully-injected hemispheres. In total, we
successfully light-evoked currents from 34 of 42 (81%) BNST neurons that we patched in
these slices. Injection site “misses” that resulted in unsuccessful virus infection in the CeA
yielded no fluorescent signal or light-evoked IPSCs in the BNST (data not shown). These
findings confirmed that this animal model was suitable to functionally probe the CeA-BNST
pathway using an optogenetic approach.
In order to examine whether inhibitory projections from the CeA to the BNST target a
specific type of cell in the BNST, we examined whether there was a relationship between
any basal physiological properties (membrane capacitance, membrane resistance,
hyperpolarization-activated current) and the peak amplitude of light-evoked IPSCs from
each cell we patched. No cellular properties were correlated with the magnitude of the
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postsynaptic response, nor were there any significant differences in the magnitude of any of
these properties between neurons that could be successfully light-evoked and those that
could not. When we evaluated the ability of the KOR agonist, U69593, to modulate the
CeA-BNST GABAergic synapse, we found that application of 1 μM U69593 led to a
significant reduction in light-evoked IPSCs (71 ± 20% of baseline, p < 0.05, n =6, Figure
7D) as it did in electrically-evoked IPSCs.
Discussion
KOR signaling has been shown to be involved in stress-induced alterations in behavior, but
few studies have examined the impact of KOR signaling on synaptic transmission in brain
regions that regulate affective behavior. Here we provide the first evidence demonstrating
that KOR signaling depresses GABAergic synaptic transmission in the BNST via a
presynaptic mechanism. Further, we provide evidence suggesting that this form of
modulation is mediated by ERK activation. Finally, using a knock-in mouse combined with
an inducible viral optogenetic approach, we show that KOR signaling can modulate the CeA
to BNST GABAergic pathway as detailed in Figure 7E.
KOR activation leads to presynaptic inhibition of GABAergic transmission in the BNST
We provide multiple lines of evidence that KOR activation modulates inhibitory
transmission in the BNST via a presynaptic mechanism, consistent with previous studies
demonstrating that opioid peptides, including dynorphin, modulate synaptic transmission
presynaptically (28–30). First, the inhibitory effect of U69593 was increased in reduced
extracellular calcium concentration, as has been shown with other forms of presynaptic
modulation (21). Second, KOR activation reduced the frequency, but not amplitude, of both
spontaneous and miniature IPSCs. Third, there was a significant increase in CV, a measure
sensitive to both release probability and the number of neurotransmitter release sites (22).
Interestingly, the effect of KOR activation on CV but not PPR suggest that this may be
through a reduction in the number of release sites, rather than a reduction in the probability
of GABA release. This is similar to how norepinephrine inhibits glutamatergic synaptic
function in the CeA via α2A-adrenergic receptors (31). Alternatively, it is possible that the
magnitude of the effect is not sufficient to cause observable changes in PPR.
A novel role for ERK signaling in KOR-mediated inhibition of GABAergic transmission
The ERK signaling cascade plays a critical role in a wide variety of cell regulatory events
and behavioral responsivity (32–34). The ability of KOR to activate ERK signaling has been
well characterized both in cell culture (35) and in vivo (24, 26). A large body of evidence
has demonstrated that the ERK pathway plays a critical role in regulation of glutamatergic
transmission and plasticity (36, 37), with a principal focus on postsynaptic modulation of
function. In contrast, there has been little investigation in to the ability of ERK signaling to
modulate GABAergic transmission, and to date, there is only one report of ERK signaling
regulating GABA release. This study demonstrated that the behavioral deficits in a mouse
model for neurofibromatosis type 1 were due to an ERK-dependent increase in GABA
release in the hippocampus, potentially via phosphorylation of synapsin (38). It is currently
unclear how KOR directed ERK activation is linked to inhibition of GABA release, but this
may be a novel action by which ERK can influence cellular and/or network function.
Implications for KOR modulation of GABAergic transmission in the BNST
The projection from the CeA to the BNST has been proposed to play a critical role in the
regulation of anxiety behavior (39). Supported by recent studies from the Winder lab (16,
40), this model suggests that neurons in the CeA that project to the BNST release CRF to
enhance glutamate release, leading to increased anxiety (39). Based on evidence that a
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portion of CRF neurons in the CeA co-express dynorphin (18) and our results that KOR
activation inhibits GABA release in the CeA to BNST pathway, we hypothesize that CRF
and dynorphin act in concert to increase anxiety-like behavior. The net effect of both
decreasing inhibitory transmission (KOR activation) and increasing excitatory transmission
(CRF) at synapses with potential BNST projection neurons likely enhances the output of the
BNST to downstream structures directly involved in the regulation of affective/anxiety-
related behaviors. This hypothesized interaction between dynorphin and CRF is supported
by findings from the Chavkin group that have suggested that the dysphoric actions of CRF
are mediated in part through the activation of KOR (41) . While we hypothesize that the
CeA serves as a source of dynorphin to the BNST, it is also possible that this dynorphin
could originate within the BNST or the paraventricular nucleus of the hypothalamus.
Conclusions
The results from this study add to a growing body of evidence suggesting that the KOR
system is involved in the regulation of affective neuronal circuitry. We provide the first
evidence that dynorphin modulates synaptic transmission in the BNST, a brain region that
has been strongly implicated in a range of affective disorders, including post-traumatic stress
disorder (PTSD), anxiety and depression. Further, we provide the first evidence that ERK is
involved in the actions of KOR at GABAergic synapses. Based on these findings, as well as
the larger body of literature focused on the role of BNST in maintaining organismal
homeostasis, we speculate that negative modulators of KOR-directed ERK signaling may
prove a successful treatment strategy for stress-induced affective disorders.
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Figure 1. Kappa Opioid Receptor (KOR) activation reduces synaptic inhibition in the BNST
A) Representative experiment demonstrating the ability of Dynorphin A (300 nM) to reduce
the peak amplitude of eIPSCs in the BNST. Inset: average traces from the representative
experiment showing the effects before (black) and after (red) application of Dynorphin A.
B) Pooled data demonstrating that the ability of 300 nM dynorphin to reduce eIPSC peak
amplitude is blocked by pre-application of the KOR receptor antagonist, nor-BNI (100 nM).
C) Pooled data demonstrating that 100 nM nor-BNI reverses the Dynorphin A effect on
eIPSC amplitude. D) Pooled data demonstrating that the ability of the KOR agonist,
U69593, to inhibit eIPSC amplitude is blocked by the KOR antagonist nor-BNI in the
BNST. E) Pooled data demonstrating no tonic activation of KORs by endogenous
Li et al. Page 11













dynorphin. F) Summary of magnitude of maximal inhibition produced by bath-application
of drugs in A–E.
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Figure 2. KOR inhibition is increased in reduced external calcium
A) Pooled data demonstrating that reducing the external concentration of calcium to 1.0 mM
(n = 5) leads to an increased effect of U69593 (2.0 mM calcium data replotted from Figure 1
for comparison). B) Bar chart demonstrating the significantly increase in U69593-mediated
inhibition in 1.0 mM calcium.
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Figure 3. KOR activation reduces sIPSC and mIPSC frequency but not amplitude
A & B) Representative baseline (A) and post-drug (B) traces demonstrating the effect of
U69593 on spontaneous GABAergic transmission in the BNST. C & D) Cumulative
probability distribution of peak amplitude (C) and frequency (D) before (black) and after
(red) application of U69593, demonstrating no effect on amplitude but a reduction in
frequency. E) Pooled data demonstrating that U69593 reduces sIPSC frequency but not
amplitude. F) Pooled data demonstrating that U69593 reduces mIPSC frequency but not
amplitude.
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Figure 4. Evaluation of CV/PPR as means to determine presynaptic versus postsynaptic changes
in synaptic transmission in the BNST
A) Representative paired pulse traces at baseline and following application of 100 nM
baclofen (red). B) The same traces from panel A normalized to highlight the effect of
baclofen on the paired pulse ratio. C & D) Pooled results demonstrating the effect of
baclofen on eIPSC amplitude (C) and PPR (D). E & F) Pooled results demonstrating the
effect of reduced stimulation on eIPSC amplitude (E) and PPR (F). G & H) Pooled results
demonstrating the effect of sub-saturating picrotoxin (5 μM) on eIPSC amplitude (G) and
PPR (H). I & J) Summary bar graphs demonstrating the effects drug treatments on PPR (I)
and coefficient of variation (J).
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Figure 5. Effect of KOR activation on PPR/CV in the BNST
A) Pooled data demonstrating the lack of an effect of Dynorphin A on PPR. (B) Pooled data
demonstrating the lack of an effect of U69593 on PPR. C) Summary bar chart demonstrating
the lack of an effect of either KOR agonist on PPR in the BNST. D) Bar chart demonstrating
the significant effects of Dynorphin A and U69593 on CV in the BNST.
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Figure 6. ERK, but not p38, signaling is required for KOR-mediated inhibition of GABA release
in the BNST
A) Pre-incubation of brain slices with the p38 map kinase inhibitor SB204580 (20 μM) did
not alter the ability of U69593 to reduce eIPSC peak amplitude in the BNST, while pre-
incubation of the MEK inhibitors, U0126 (20 μM) and SL327 (10 μM) led to significant
impairment in the ability of U69593 to modulate GABA transmission in the BNST. B)
Summary of the impact of MAPK inhibitors on KOR-mediated inhibition. C) Both MEK
inhibitors, U0126 (20 μM) and SL327 (10 μM), bath-applied alone increased eIPSC
amplitude in the BNST. D) Summary of the effects of MEK inhibitors on GABA
transmission in the BNST. E) Pre-incubation of brain slices with the MEK inhibitor, U0126
(20 μM), did not alter the ability of baclofen to modulate GABA transmission in the BNST.
F) Summary of the impact of U0126 on baclofen-mediated inhibition of GABA transmission
in the BNST.
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Figure 7. KOR activation inhibits CeA to BNST GABAergic transmission
A & B) Injection of an AAV-expressing, Cre-inducible GFP in the CeA resulted in GFP
positive neurons in the CeA (A) and a large number of GFP positive fibers in the
dorsolateral BNST. C) A brief flash of blue-light leads to a depolarization of GABAergic
cell bodies in the CeA (i), and an inhibitory post-synaptic current (IPSC) in a BNST neuron
(ii), which was completely blocked by the GABAA-R receptor antagonist picrotoxin (25
μM), demonstrating that this current is mediated via GABAA receptors. D) Pooled data
demonstrating that the KOR agonist, U69593, inhibits light-evoked IPSC amplitude in the
CeA-BNST pathway. E) Model summarizing the results of this study.
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